SCHEMBL24308331

SCHEMBL24308331

O=C(NO[C@H](Cc1ccccc1)C(=O)O)OCc1cccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 1/20 0.48
EPHX1 P07099 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
SRR Q9GZT4 2/20 0.46
HRH4 Q9H3N8 1/20 0.46
TGM2 P21980 1/20 0.45
CASP1 P29466 3/20 0.45
FFAR1 O14842 1/20 0.44
AKR1B1 P15121 1/20 0.44
ATM Q13315 1/20 0.41
HSP90AA1 P07900 2/20 0.41
HSP90AB1 P08238 2/20 0.41
CTNNB1 P35222 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24307999 1.00 PSMB5 (0.48) PSMB5EPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL24307964 0.86 EPHX1 (0.48) EPHX1SLC1A3SLC1A2SLC1A1TGM2
SCHEMBL24307995 0.86 EPHX1 (0.48) EPHX1SLC1A3SLC1A2SLC1A1TGM2
SCHEMBL24308341 0.85 PSMB5 (0.48) PSMB5EPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL24307962 0.85 PSMB5 (0.48) PSMB5EPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL24308004 0.84 EPHX1 (0.46) EPHX1SLC1A3SLC1A2SLC1A1TGM2
SCHEMBL24307955 0.83 SRR (0.57) SLC1A3SLC1A1PPARGPPARASRR
SCHEMBL9551280 0.83 SRR (0.57) SLC1A3SLC1A1PPARGPPARASRR
SCHEMBL24307990 0.83 SRR (0.57) SLC1A3SLC1A1PPARGPPARASRR
SCHEMBL24307968 0.83 TGM2 (0.48) EPHX1SLC1A3SLC1A2SLC1A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-11-23 US disclosed
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-11-23 US disclosed
WO-2022075486-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS NOTCH1, NOTCH2, HES1 PSMB5 4700/4885EPHX1 2685/4885SLC1A3 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.